After the tax bill went into effect nearly a year ago, the pharmaceutical industry was predicted to have many more funds at its disposal, since huge amounts of offshore cash could be repatriated. But what have drug makers done with the money? Mostly, the cash has been used for share repurchases, debt reduction, and some acquisitions, according to a report from Moody’s Investor Service.

To be specific, the 10 largest drug makers had cash holdings — cash and fixed-income investments — of $155 billion at the end of the third quarter, down from $193 billion at the end of 2017. And much of the cash has been spent on returning money to stockholders, although this was not a surprise, according to Moody’s analyst Michael Levesque.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy